Polarix: A Phase 3 Study of Polatuzumab Vedotin (Pola) Plus R-CHP Versus R-Chop in Patients (Pts) With Untreated DLBCL

Hematological Oncology - United Kingdom
doi 10.1002/hon.36_2629
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Polatuzumab Vedotin (Pola) + Obinutuzumab (G) + Lenalidomide (Len) in Patients (Pts) With Relapsed/Refractory (R/R) Follicular Lymphoma (Fl): Phase Ib/Ii Interim Analysis

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Da-Epoch-R Versus R-Chop in High Risk DLBCL Patients: Analysis of the Czech Lymphoma Study Group (Clsg)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

ROBUST: First Report of Phase III Randomized Study of Lenalidomide/R-Chop (R2 -CHOP) vs Placebo/R-Chop in Previously Untreated ABC-type Diffuse Large B-Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Elevated Expression of Lag3 Is Associated With Poor Outcome in Patients With DLBCL Treated With R-Chop

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Phase Ii Study of Durvalumab (Anti-Pd-L1) Combined With Either R-Chop or Lenalidomide and R-Chop in Previously Untreated, High-Risk Diffuse Large B-Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Decitabine Plus R-Chop in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma: Interim Results of a Phase I/Ii Study

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Negative Impact of Zoledronic Acid in R-Chop Treated DLBCL With Bone Metastasis

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

A Phase 1/2 Study of Brentuximab Vedotin in Pediatric Patients With Relapsed/Refractory (R/R) Systemic Anaplastic Large-Cell Lymphoma (Salcl) or R/R Hodgkin Lymphoma (Hl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

HEALTH-RELATED QUALITY OF LIFE (HRQoL) IN RELAPSED/REFRACTORY (R/R) INDOLENT NHL IN THE PHASE 3 AUGMENT TRIAL OF RITUXIMAB (R) PLUS LENALIDOMIDE (R2 ) VERSUS R PLUS PLACEBO

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy